DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
Acknowledgment is made of applicant’s claim for foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed on June 27, 2024.
Information Disclosure Statement
The information disclosure statements (IDS) submitted on January 27, 2025 and February 02, 2025 have been considered by the examiner.
Claim Objections
Claim 1 is objected to because of the following informalities:
In claim 1, line 1, it is suggested that “The” be replaced with --A--.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
Claims 1-10 and 13-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
In claim 1, lines 5-6, it is unclear whether the natural adhesive agent is added to the polyhydroxyalkanoate and organic solvent during the first dissolution step.
In claim 1, line 11, it is unclear whether “said binding mixture” further includes the natural adhesive agent.
In claim 2, line 2, it is unclear how the narrower recitation “preferably chloroform” limits the antecedently-recited broader recitation “organic solvent”. The claim is considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claim.
In claims 8 and 13, lines 4-5, it is unclear what is meant by “chemically-modified” vegetable oils.
In claims 8 and 13, line 5, it is unclear whether a combination of natural oils AND fats of recovery from the food industry is recited.
Claim Rejections - 35 USC § 102/103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1, 2, 4, 5 and 11 are rejected under 35 U.S.C. 102(a1) and (a2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over US 2003/0094715 (Suzuki)
Suzuki discloses a method of making an emulsion wherein an organic phase containing an organic solvent having a boiling point lower than that of water, a hardly-water-soluble biodegradable polyester and a medicament is emulsified in an aqueous phase containing an emulsifier and water (e.g., abstract, [0013], [0039-0047], [0051-0057], [0061-0089], examples, claims). Notably, the organic solvent includes chloroform [0044], the biodegradable polyester includes those derived from hydroxybutyric acid [0047], the medicament includes peptides, hormones, vitamins [0061-0088] and the emulsifier includes polyvinyl alcohol [0056]. The emulsion can be used to prepare aqueous inks and liquid medicament formulations [0146-0148]. Suzuki’s method for preparing the emulsion comprises:
dissolving the biodegradable polyester in the organic solvent to form the organic phase;
adding a medicament to the organic phase;
dissolving the emulsifier in water to form the aqueous phase;
emulsifying the organic phase with the aqueous phase; and
removing at least part of the organic solvent (e.g., [0013], [0039]).
As to claim 1, Suzuki expressly exemplifies (Examples 5-9) emulsion products obtained by:
dissolving lactic acid-glycolic acid copolymer in methylene chloride to obtained a solution (meets Applicants’ first dissolution step wherein the polyhydroxyalkanoate is lactic acid-glycolic acid copolymer and the organic solvent is methylene chloride);
adding vitamin B12 to the above solution to form an organic phase (meets Applicants’ addition step wherein the natural adhesive agent is vitamin B12);
dissolving polyvinyl alcohol in water to form an aqueous phase (meets Applicants’ second dissolution step wherein the emulsifier is polyvinyl alcohol);
emulsifying the organic phase with the aqueous phase (meets Applicants’ emulsion step); and
removing at least part of the organic solvent to obtain the product (meets Applicants’ organic solvent removal step).
Suzuki’s emulsions are used to prepare aqueous inks and liquid medicament formulations [0146-0148] (meets Applicants’ generically-recited painting product).
As to claim 2, Suzuki expressly exemplifies the halogenated organic solvent methylene chloride.
As to claim 4, in Suzuki’s Example 5 the vitamin B12 is added in a quantity of about 11 wt.% of the lactic acid-glycolic acid copolymer.
As to claim 5, in Suzuki’s Example 5 the aqueous phase comprises 0.5 wt.% polyvinyl alcohol.
As to claim 11, in Suzuki’s exemplified emulsion products the dispersing phase comprises water and polyvinyl alcohol and the dispersed phase comprises lactic acid-glycolic acid copolymer and vitamin B12.
Suzuki anticipates the above rejected claims in that it is reasonably believed that the exemplified lactic acid-glycolic acid copolymer and vitamin B12 fall within the corresponding components presently claimed. In the alternative, it would have been within the purview of Suzuki’s inventive disclosure, and obvious to one having ordinary skill in the art, to use a biodegradable polyester derived from hydroxy fatty acids such as hydroxybutyric acid in place of the exemplified lactic acid-glycolic acid copolymer and another natural medicament in place of the exemplified vitamin B12 for their expected additive effects and with the reasonable expectation of success.
Claim Rejections - 35 USC § 103
Claims 3, 6-8, 12 and 13 are rejected under 35 U.S.C. 103 as being unpatentable over US 2003/0094715 (Suzuki) described hereinabove.
As to claim 3, it is within the purview of Suzuki’s inventive disclosure [0050], and obvious to one having ordinary skill in the art, to dissolve the biodegradable polyester in amounts inclusive of those presently claimed in accordance with the desired properties and with the reasonable expectation of success. In general, differences in concentrations do not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating criticality for the claimed ranges. “Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation”, In re Aller, 105 USPQ 233.
As to claim 6, it is within the purview of Suzuki’s inventive disclosure [0055], and obvious to one having ordinary skill in the art, to use the presently recited volume ratios of organic phase to aqueous phase in accordance with the desired properties and with the reasonable expectation of success. In general, differences in concentrations do not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating criticality for the claimed ranges. “Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation”, In re Aller, 105 USPQ 233.
As to claim 7, it is within the purview of Suzuki’s inventive disclosure, and obvious to one having ordinary skill in the art, to further include boric acid or citric acid [0149] (meets Applicants’ crosslinking agent) for its expected additive effect and with the reasonable expectation of success.
As to claims 8 and 13, it is within the purview of Suzuki’s inventive disclosure [0061-0082], and obvious to one having ordinary skill in the art, to use a peptide (natural protein) as the medicament in accordance with the desired properties and with the reasonable expectation of success.
As to claim 12, it is within the purview of Suzuki’s inventive disclosure [0047-0048], and obvious to one having ordinary skill in the art, to use a biodegradable polyester derived from hydroxy fatty acids such as hydroxybutyric acid in accordance with the desired properties and with the reasonable expectation of success. The selection of a known material based on its suitability for its intended use supports a prima facie case of obviousness, Sinclair & Carroll Co. v. Interchemical Corp., 65 USPQ 297.
Claims 9, 10, 14 and 15 have not been incorporated into this rejection because it is not seen that Suzuki discloses or suggests the presently claimed natural adhesive agents.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ana L Woodward whose telephone number is (571)272-1082. The examiner can normally be reached M-F 8am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ANA L. WOODWARD/Primary Examiner, Art Unit 1765